Halozyme Therapeutics HALO Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's free cash flow yield?
- Halozyme Therapeutics (HALO) reported free cash flow yield of 8.7% in Q1 2026.
- How has Halozyme Therapeutics's free cash flow yield changed year-over-year?
- Halozyme Therapeutics's free cash flow yield increased by 38.6% year-over-year, from 6.3% to 8.7%.
- What is the long-term trend for Halozyme Therapeutics's free cash flow yield?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's free cash flow yield has grown at a 55.4% compound annual growth rate (CAGR), from 0.9% to 8.1%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.